Immunome INC Form 4 insider transactions

Immunome Inc. Director Isaac Barchas reported the sale of 383,200 common shares through pre-arranged trading plans.

Immunome Inc.'s Chief Scientific Officer, Jack Higgins, gifted 3,000 shares of common stock to custodial accounts for his children.

Immunome Inc.'s President and CEO, Clay B. Siegall, acquired 7,278 shares of common stock while gifting 200,000 shares to a grantor retained annuity trust.

Immunome Inc.'s Chief Technical Officer, Philip Tsai, acquired 10,000 shares of common stock at $20.49 per share.

Immunome Inc.'s President and CEO, Clay B. Siegall, purchased 46,511 shares of common stock at $21.50 per share in a public offering.

Immunome's Chief Scientific Officer, Jack Higgins, exercised stock options to acquire 22,000 shares of common stock at $1.35 per share.

Immunome Inc.'s Chief Technical Officer, Philip Tsai, was granted 190,000 employee stock options with an exercise price of $10.60, aligning executive incentives with shareholder value.

Immunome Inc.'s Chief Financial Officer, Max Rosett, was granted 207,000 employee stock options with an exercise price of $10.60 per share.

Immunome Inc.'s Chief Medical Officer, Robert Lechleider, was granted 242,000 employee stock options with an exercise price of $10.60, vesting over time.

Immunome Inc.'s Chief Business Officer, Kinney Horn, was granted 161,000 employee stock options with an exercise price of $10.60, vesting over time.

Immunome Inc.'s Chief Scientific Officer, Jack Higgins, was granted 196,000 employee stock options with an exercise price of $10.6, vesting over several years.

Immunome Inc.'s President and CEO, Clay B. Siegall, was granted 800,000 employee stock options with an exercise price of $10.60 per share, vesting over time.

Immunome Inc.'s Chief Legal Officer and General Counsel, Sandra G. Stoneman, was granted 190,000 employee stock options with an exercise price of $10.6 per share.

Immunome Inc. Director James P. Boylan was granted 18,864 stock options with an exercise price of $9.57, though he disclaims beneficial ownership, holding them for the benefit of Enavate Sciences, LP.

Immunome Inc. director Carol Schafer was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year, aligning her interests with long-term shareholder value.

Immunome Inc. Director Philip Wagenheim was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year.

Immunome Inc. Director Isaac Barchas was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year starting June 10, 2025.

Immunome Inc. Director Jean Jacques Bienaime was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year.

Immunome Inc. Director Sandra M. Swain was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year, as part of her compensation.

Immunome Inc. Director Jean Jacques Bienaime acquired 5,000 shares of the company's common stock at a weighted average price of $9.38 per share on June 3, 2025, increasing his direct beneficial ownership to 36,415 shares.

Jack Higgins, Chief Scientific Officer of Immunome Inc., exercised stock options to acquire 5,200 shares of common stock at $1.35 per share on March 27, 2025.

Director Jean Jacques Bienaime purchased 7,800 shares of Immunome Inc. (IMNM) at an average price of $7.78 on March 25, 2025.

Immunome's President and CEO, Clay B. Siegall, recently purchased 137,100 shares of the company's common stock at an average price of $7.29 per share.

Director Jean Jacques Bienaime of Immunome Inc. reports the acquisition of 7,000 shares of common stock at an average price of $8.21.

Philip Tsai, Chief Technology Officer of Immunome Inc., reports the acquisition and disposal of common stock on March 24, 2025.

Immunome's CEO, Clay B. Siegall, purchased 150,000 shares of common stock at $7.75 per share as part of a recent public offering.

Immunome's CEO, Clay B. Siegall, acquired a total of 100,000 shares of common stock in two open market transactions.

Immunome Inc.'s Chief Medical Officer, Robert Lechleider, purchased 15,805 shares of common stock at a price of $9.478 per share.

Immunome Inc.'s Chief Technology Officer, Philip Tsai, acquired 21,000 shares of common stock at a price of $9.43 per share on November 21, 2024.

Immunome's Chief Financial Officer, Max Rosett, exercised stock options and sold shares to cover the transaction on September 19, 2024.